Original ArticleNon–Small Cell Lung CancerPhase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis
Keywords
Cited by (0)
Disclosure: Planchard acts as a principal investigator/coinvestigator at AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, MedImmune, Sanofi-Aventis, Taiho Pharma, Novocure, and Daiichi Sankyo; and acts as advisory and reports receiving personal fees from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Celgene, Daiichi Sankyo, Merck, Novartis, Pfizer, priME Oncology, Peer CME, Roche, and Samsung. Besse reports receiving grants from Inivata, Janssen, Merck KGaA, Merck Sharp & Dohme, Nektar, Onxeo, OSE Immunotherapeutics, Pfizer, PharmaMar, Roche-Genentech, Sanofi, Serier, Spectrum Pharmaceuticals, Takeda, Tiziana Pharma, and Tolero Pharmaceuticals. Groen acts as an advisor for Eli Lilly and investigator for Novartis and Boehringer Ingelheim. Mazieres reports receiving grants from Roche, AstraZeneca, and Pierre Fabre; and acts as advisor for Merck, Roche, AstraZeneca, Merck Sharp & Dohme, Bristol-Myers Squibb, Pfizer, Hengrui Therapeutics, Daiichi, Boehringer, Pierre Fabre, and Amgen. Kim reports having consulting/advisory roles at AstraZeneca, Boryung, Hanmi, Eli Lilly, Novartis, Takeda, Sanofi, and Roche/Genentech and receiving a grant from AstraZeneca-KHIDI. Quoix reports receiving grants and personal fees from Bristol-Myers Squibb; personal fees from Chugai; and grants from Roche, Takeda, and Medscape interview during the American Society of Clinical Oncology 2019. Souquet reports receiving grant, personal fee, and nonfinancial support from Novartis. Barlesi reports receiving personal fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly Oncology, F. Hoffmann–La Roche Ltd., Novartis, Merck, Merck Sharp & Dohme, Pierre Fabre, Pfizer, and Takeda. Baik reports receiving grants from LOXO Oncology, Spectrum Pharmaceuticals, Pfizer, Blueprint Medicines, Daiichi Sankyo, AbbVie, Rain Therapeutics, Turning Point Therapeutics, AstraZeneca, Hoosier Caner Research Network, Novartis, Genentech Inc., and personal fees from AstraZeneca, BluePrint Medicine, and Daiichi Sankyo. Villaruz reports receiving grants from Merck, Celgene, Eli Lilly, Genentech, AstraZeneca, Incyte, Rain Therapeutics, Exelixis, Bristol-Myers Squibb, and GlaxoSmithKline, and personal fees from Achilles and Daiichi Sankyo. Kelly acts as advisory for Bristol-Myers Squibb, Novartis, Eli Lilly, AstraZeneca, Merck, Takeda, Daiichi Sankyo, and EMD Serono and reports receiving grants from Eli Lilly and Bristol-Myers Squibb. Zhang reports employment for Novartis. Tan reports employment for Novartis. Gasal reports employment for Novartis. Santarpia reports employment for Novartis. Dr. Johnson reports receiving grants from Cannon Medical Systems, grants and personal fees from Novartis, and personal fees from Hengrui Therapeutics, Daiichi Sankyo, Checkpoint Therapeutics, Lilly, and G1 Therapeutics; has a patent EGFR Mutation Testing with royalties. Hashemi declares no conflict of interest.